Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed-drug combinations in India under the brand names Glempa, Glempa-L, and Glempa-M. The shares of Glenmark ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M ...

The drug has been introduced under the brand name Glempa (empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (empagliflozin 10/25 mg + linagliptin 5 mg) and Glempa-M ...

Glenmark Pharmaceuticals announced that it has launched generic Empagliflozin, a widely recognized SGLT2 inhibitor, in India.

Glenmark launched empagliflozin under the brand name Glempa, along with fixed-dose combinations. The company price 10mg dosage at Rs 11 per tablet and 25 mg at 14 per tablet. "The launch of Glempa ...

Stock Market LIVE Updates | India's equity benchmark indices Sensex and Nifty were flat on Wednesday, as gains in Reliance Industries and Bharti Airtel, following their deals with Elon Musk's SpaceX ...

Glenmark Pharmaceuticals has introduced Glempa, a medication designed for glycemic control and weight-loss in type 2 diabetes patients. The drug, an SGLT2 inhibitor, aims to improve cardiovascular ...

The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations ...